GlassScriptPhysician profile
Lindsay A Rhodes
NPI 1396999587
$17,996.53
in general payments reported to CMS, 2019-2025
19 companies · $6,511 in 2025
The $6,511 reported for 2025 was more than what 94% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,504 · 2020: $88.68 · 2021: $3,068 · 2022: $226 · 2023: $378 · 2024: $3,221 · 2025: $6,511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,725 · Food and Beverage: $2,345 · Travel and Lodging: $1,041.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,725.00 |
| Food and Beverage | $2,344.51 |
| Travel and Lodging | $1,040.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $6,486.02 | 2021-2025 | Clareon, Lensx, Clareon Panoptix Pro |
| Johnson & Johnson Surgical Vision, INC. | $5,680.15 | 2019-2025 | Tecnis Simplicity, Tecnis Iol, Tecnis Iol |
| Carl Zeiss Meditec, INC. | $4,308.28 | 2019 | |
| Abbvie INC. | $673.51 | 2023-2025 | |
| Aerie Pharmaceuticals, INC. | $287.60 | 2019-2021 | |
| Topcon Healthcare, INC. | $108.71 | 2022 | |
| Shire North American Group INC | $99.70 | 2019 | |
| Sight Sciences, INC. | $83.53 | 2024 | Omni Surgical System |
| Glaukos Corporation | $48.55 | 2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Oyster Point Pharma, INC. | $39.38 | 2025 | Tyrvaya |
| Dompe US, INC. | $29.04 | 2025 | Oxervate |
| New World Medical,INC. | $22.88 | 2025 | Clearpath, Streamline, Via360 |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $22.11 | 2025 | |
| Thea Pharma INC. | $20.82 | 2025 | Iyuzeh |
| Sun Pharmaceutical Industries INC. | $20.57 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $17.66 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.72 | 2020 | |
| Novartis Pharmaceuticals Corporation | $15.70 | 2019 | |
| Harrow Eye, LLC | $15.60 | 2025 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Rhodes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.